SCHEMBL325899

SCHEMBL325899

CCc1cccc(OCc2cncs2)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 1/20 0.47
PARP10 Q53GL7 1/20 0.47
SOD1 P00441 1/20 0.47
ALOX5 P09917 1/20 0.44
SNRNP200 O75643 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ACACB O00763 1/20 0.41
BCHE P06276 1/20 0.40
MAPK1 P28482 2/20 0.39
TSHR P16473 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12015518 0.82 PARP15 (0.49) PARP15PARP10SNRNP200ALDH1A1SMN1; SMN2
SCHEMBL15607657 0.81 PARP15 (0.43) PARP15PARP10ALOX5SNRNP200TDP1
SCHEMBL15607658 0.81 PARP15 (0.54) PARP15PARP10ALOX5SNRNP200TDP1
SCHEMBL13347808 0.80 L3MBTL1 (0.69) SOD1TDP1L3MBTL1ALDH1A1KDM4E
SCHEMBL278312 0.79 ALOX5 (0.48) PARP15PARP10SOD1ALOX5SNRNP200
SCHEMBL17307635 0.77 PARP15 (0.50) PARP15PARP10ALOX5SNRNP200TDP1
SCHEMBL15474277 0.77 PARP15 (0.47) PARP15PARP10ALOX5SNRNP200TDP1
SCHEMBL18347810 0.77 PARP15 (0.44) PARP15PARP10ALOX5SNRNP200TDP1
SCHEMBL28406646 0.76 PARP15 (0.46) PARP15PARP10ALOX5SNRNP200TDP1
SCHEMBL13505522 0.75 NOS3 (0.44) PARP15PARP10TDP1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133898-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-13 US disclosed
US-20100137310-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137310-A1 RENIN INHIBITORS REN, ACE, PRSS3 PARP15 801/4885PARP10 1691/4885SOD1 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.